Background: Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the MET tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic ASPS.
Introduction
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma (STS) with high metastatic potential, accounting for 0.5%-1% of all STS [1] [2] [3] [4] [5] [6] [7] . Typical metastatic sites include brain, lungs, lymph nodes and bone [2, 4, 5] . According to the literature, the 5-year survival is only 20% in patients with metastases versus 71% in patients with localised disease [6] .
Complete excision of the primary tumour can cure ASPS, but due to late diagnosis and early metastatic spread it is not an option for all patients [2] . Patients with advanced, inoperable and/ or metastatic disease qualify for systemic treatment, but conventional chemotherapy has little efficacy [2, 4] .A number of targeted agents are currently being tested in ASPS.
ASPS is characterised by the presence of a somatic translocation between chromosomes 17 and X (supplementary Figures S1 and S2, available at Annals of Oncology online), resulting in the ASPSCR1-TFE3 fusion gene (supplementary Introduction and Figure S3 , available at Annals of Oncology online) [5, 8, 9] .The ASPSCR1-TFE3 fusion gene plays a critical role in the development of ASPS as it encodes a chimeric transcription factor, inducing an overexpression of the MET gene, encoding the MET receptor tyrosine kinase (supplementary Figure S4 , available at Annals of Oncology online) [2, 3, 5, 7, 8] .
In normal cells the hepatocyte growth factor activates the MET receptor resulting in a downstream cascade of events that regulate cell proliferation and differentiation [10] . In a variety of cancers, MET gets abnormally activated leading to abnormal cell division and survival, invasion and metastasis, resulting in a poor prognosis [4, 7, 10, 11] .
The presence of MET activation and overexpression in ASPS provides a rationale to therapeutically target MET in this disease. Crizotinib (Xalkori V R , Pfizer Inc., New York) is a small molecule targeting: MET, anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) [12] [13] [14] [15] . Crizotinib interferes with the MET pathway by competitively inhibiting ATP from binding to the receptor, therefore abrogates its phosphorylation [12] [13] [14] [15] . This blocks the downstream cascade of events, thereby inhibiting the growth and survival of MET dependent cells [12] [13] [14] [15] . Crizotinib is indicated in adult patients for ALK-positive non-small-cell lung cancer (NSCLC), and ROS1-positive advanced NSLCL [15] , and the recommended oral dose in adults is 250 mg bd.
The European Organization for Research and Treatment of Cancer (EORTC) initiated a multinational, multitumour, prospective phase II clinical trial (EORTC 90101 'CREATE') to evaluate the efficacy and safety of crizotinib in patients with advanced tumours driven by MET and/or ALK alterations.
CREATE included six disease-specific groups, and we report here the results of the independent ASPS cohort.
Methods

Study design
This was a multicentre, biomarker-driven, single agent, nonrandomized, open-label, two-stage phase II trial, assessing crizotinib in patients with locally advanced/metastatic ASPS. The patient population was divided by protocol into MET altered (METþ) and MET non-altered (METÀ) sub-cohorts, assessed by the presence of TFE3 rearrangement. Both cohorts were analysed separately.
Ethics approval was obtained for this study (ClinicalTrials.gov identifier NCT01524926), which was conducted in accordance with the Declaration of Helsinki, International Conference on HarmonisationGood Clinical Practice, and participating country and institution regulations.
Patient enrolment
Patient enrolment was based on a multistep registration procedure.
Step 1 prerequisites for registration were a local diagnosis of advanced and/or metastatic ASPS deemed incurable by conventional surgery, radiotherapy or systemic therapy, the availability of a formalin-fixed paraffin-embedded tumour-containing tissue block from primary tumour and/or metastatic site, and written informed consent of the patient for central collection of tissue and all other trial-specific procedures.
Criteria for step 2 included receipt of the tissue by a central biorepository (BioRep, Milan, Italy) with the presence of tumour in the shipped material and confirmation of the correct diagnosis of ASPS by central reference pathology.
Screened patients were treated after completion of both steps, provided all other eligibility criteria were met. Details on patient selection and prior treatments are described in the study protocol (http://www. eortc.be/services/doc/protocols/90101v10.0.pdf).
Documentation of the presence of TFE3 rearrangement was not required for a patient to enter the treatment phase (step 3). FISH analysis was done while patients were already receiving therapy, to avoid delaying start of treatment of patients in need for an experimental treatment.
Treatment, safety and efficacy assessment
Eligible patients with centrally confirmed ASPS were treated with oral crizotinib at a starting dose of 250 mg bd. One treatment cycle was defined as 21 days. Treatment, dose and schedule modifications were defined in the protocol.
Tumour assessments were done based on RECIST 1.1 using computer tomography or magnetic resonance imaging of chest, abdomen and pelvis. Baseline scans were not older than 28 days at study entry. The radiological assessment was done locally every 6 weeks and repeated to confirm objective responses at least 4 weeks after the initial documentation of a response. Objective responses were reviewed centrally.
Safety information was collected using the Common Terminology Criteria for Adverse Events (CTCAE) version: 4.0.
Assessment of TFE3 rearrangement
Patients were attributed to METþ or METÀ sub-cohorts on the basis of the presence or absence of a TFE3 gene rearrangement, assessed by FISH on interphase nuclei of paraffin-embedded 4 mm tumour tissue sections, using custom bacterial artificial chromosomes (BAC) RP11-344N17 and RP11-552J9 probes that flank the TFE3/Xp11.2 gene. The BAC clones were obtained from the BACPAC Resource Center (CHORI; Oakland, CA). DNA isolation, probe labelling and hybridization were carried out as described previously [16] . Slides were scored by two independent investigators and considered positive if >15% of at least 100 cells showed split signals.
Outcomes
The main objective was to study the activity of crizotinib in ASPS patients with TFE3 gene rearrangement (METþ).The primary end point was the ORR per RECIST 1.1 with response confirmation, assessed by the local investigator. This end point was chosen based on the response pattern seen with crizotinib in the labelled indication of NSCLC and due to the absence of reliable reference data on progression-free survival (PFS) or progression-free rate (PFR) in ASPS when the protocol was written. Secondary end points included: duration of response, disease control rate (DCR), PFS, PFR, overall survival (OS), overall survival rate, safety and correlative/translational research end points. DCR was defined as the percentage of patients achieving a complete, or partial response (PR) or stable disease (SD).
Statistical analysis
A Simon's optimal two-stage design was implemented separately for the ASPS METþ and METÀ sub-cohorts. The type I error and power were set at 10%. The study was conceptually focused on METþ disease, while METÀ patients served as a non-randomized, treated internal control. The entry of 'all comers' independent of their MET status allowed centres to avoid delaying treatment of patients in need of an active intervention and to provide reference data for both subsets for future clinical trials. The entry of METÀ cases was considered ethical due to the lack of validated treatment alternatives.
In stage 1, if at least two out of the first 12 eligible and assessable METþ ASPS patients achieved a confirmed RECIST PR or complete response, a maximum of 35 patients were to be enrolled. In stage 2, if <6 out of the 35 eligible and assessable patients responded, the treatment was declared ineffective. If !6 out of the 35 patients (17%) responded, further study of crizotinib was warranted. Treatment activity was declared if response rate was >10%.
Stopping rules and activity end points details are provided in supplementary Methodology, available at Annals of Oncology online. Analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC).
Results
Patient disposition, reference pathology, clinical screening and enrolment Forty-eight patients were enrolled in the study and started treatment with crizotinib (safety population: 43 METþ, 4 METÀ, 1 MET?). Reasons for not entering the treatment phase in the 5 remaining patients are shown in the trial profile (supplemen tary Figure S5 , available at Annals of Oncology online).Out of 48 patients who started treatment, 45 were eligible and assessable for the primary and secondary end points (40 METþ, 4 METÀ, 1 MET?). Two were found ineligible due to the use of specific concomitant medication or residual toxicity from prior therapy, one patient had surgery after one treatment cycle without further imaging.
Recruitment to both the METþ and METÀ sub-cohorts was suspended on 26 June 2015, with endorsement by the trial steering committee according to protocol.
Molecular analysis
FISH analysis was completed within a median time of 5 days after receipt of technically useful, unstained slides from the central biorepository.
Among the 53 patients with centrally confirmed diagnosis, 48 (90.6%) had TFE3 gene rearrangement and were defined as METþ, and 4 (7.5%) had no rearrangement detected by FISH. In one remaining patient, FISH analysis could not be carried out due to insufficient quality of the available biological material. This patient was defined as MET? Supplementary Table S1, available at Annals of Oncology online, shows an overview of the cytogenetic findings.
Patient characteristics
Characteristics of the 48 treated patients are shown in Table 1 Figure S5 , available at Annals of Oncology online).
Crizotinib study treatment
As of 19 May 2017, with a median follow-up of 833 days (range: 85-1279), 2/45 treated patients were still receiving active treatment (supplementary Figure S5 , available at Annals of Oncology online, and Table 2 ).The median relative dose intensity was 98.2%, with 27/45 treated patients requiring dose reductions or dose modifications. The treatment duration with crizotinib ranged from 2.4 to 156.1 weeks (Table 2) . Reasons for treatment discontinuation are shown in Table 2 .
METÀ patient. The responding patients progressed after 52 and 14 treatment cycles, respectively, and both are alive at the data cut-off. SD was observed in 87.5% (35/40) METþ patients, in 75.0% (3/4) METÀ patients and in the 1 MET? patient. The remainder of patients had progression. The DCR was 90% (36/40) in METþ patients (95% CI 76.3% to 97.2%) and 100% in METÀ (95% CI 39.8% to 100.0%) and the one MET? patient.
The PFR at 1 year was 37.5% (95% CI 22.9% to 52.1%), 50.0% (95% CI 5.8% to 84.5%) and 0% in METþ, METÀ, and MET? patients, respectively. The 3-and 6-month cumulative PFR in METþ patients were 85% (95% CI 73.9% to 96.1%) and 55.0% (39.6% to 70.4%) and in METÀ 75.0% (95% CI 32.6% to 100%) and 50.0% (95% CI 1.0% to 99.0). Two-year PFR is shown in Figure 1A and Table 3 .
The 1-year overall survival rate was 97.4% (95% CI 82.8% to 99.6%) in METþ patients and 75.0% (95% CI 12.8% to 96.1%) in METÀ patients. The OS at 2 years was 81.3% (95% CI 64.7% to 90.6%) in METþ patients and unchanged in METÀ patients (75.0%; 95% CI 12.8% to 96.1%) ( Figure 1B and Table 3 ). The long follow-up of this trial allows us to provide important information on the clinical course of advanced/metastatic ASPS and serves as a useful resource for future research in this rare cancer. Figure 1C illustrates the maximum target lesion shrinkage, Figure 1D summarizes the clinical course of the treated patients.
Safety and toxicity
No new, unexpected safety signals were detected in ASPS patients. The most common (overall, grade !1) crizotinib-related Autologous stem cell reinfusion for ASPS 1 (2.3) n/a n/a 1 (2.1)
Patients were attributed to MET sub-cohorts on the basis of the presence or absence of a TFE3 gene rearrangement assessed by fluorescence in situ hybridization (FISH). METþ, MET altered (>15% of at least 100 cells showed split signals); METÀ, MET non-altered; MET?, FISH analysis could not be carried out due to insufficient quality of the available biological material; n/a, not applicable. No deaths occurred on treatment or within 4 weeks of treatment discontinuation.
Discussion
Information from prospective clinical trials on the efficacy of systemic treatments for ASPS is limited. EORTC 90101 CREATE is one of the first ASPS-specific prospective studies. The main objective of this phase II study was to assess the activity of crizotinib in ASPS, a very rare and chemotherapy-resistant, translocationrelated sarcoma. The primary end point of the trial was not met, as we did not observe at least two objective and radiologically confirmed RECIST 1.1 responses among the first 12 eligible and assessable METþ cases.
Multiple factors led to overrecruitment of patients. The rapid accrual of ASPS cases, with more than half of the patients previously untreated, reflected the high unmet medical need for this orphan and hard to treat malignancy. Investigators observed a relevant proportion of patients achieving early disease stabilization with crizotinib, and all these cases could theoretically still convert, upon further exposure, to an objective response. Furthermore, all responses had to be confirmed by a second scan, to be in line with RECIST 1.1. This led to a delay in reporting efficacy data for trial participants, as investigators had to wait until their patients either came off study or had reached a confirmed PR. By that time we had exceeded the originally planned maximum sample size to assess the futility of crizotinib in METþ ASPS. In the light of the lack of validated treatment alternatives for this malignancy we accepted this overrecruitment.
The majority of our trial participants had a centrally confirmed TFE3 gene rearrangement, and none of the ASPS patients were misclassified according to central pathology review. This is likely a reflection of the increasing local use of molecular testing in many institutions in translocation-related STS. Of note, four patients had no detectable rearrangement of the TFE3 gene by FISH (classified as METÀ). It is possible that these were false negative cases due to cryptic gene rearrangements that are under microscopic visibility. This could explain also the challenging observation that some of these METÀ patients seemed to benefit from the treatment with crizotinib. Confirmation of ASPSCR1/TFE3 fusion by RT-PCR or other molecular techniques in these cases would be required to prove this notion.
Even though TFE3 rearrangement, potentially leading to altered MET expression, was present in the majority of our patients, crizotinib's inhibition of MET translated in only sporadic, but durable objective responses. It is unclear why two of our patients (one METþ and one METÀ) had exceptional responses, but we hope that further tissue-based analysis will provide an explanation. We cannot exclude that the presence of the ASPSCR1-TFE3 fusion led to different levels of altered MET expression/abnormal activation. On the other hand these responses might be induced by effects other than MET inhibition, as crizotinib affects more than one target.
Interestingly, 90% of our patients with TFE3 gene rearrangement achieved disease control and the duration of therapy was long (median number of 12.5 treatment cycles in METþ patients), suggesting that PFS or PFR would have been better primary end points. The response pattern of MET-driven malignancies to crizotinib is clearly different than the impressive volumetric responses seen in ALK-or ROS1-driven NSCLC.
Based on a retrospective statistical analysis of multiple EORTC sarcoma trials, Van Glabbeke et al. proposed reference values for potentially active agents in STS [17] . For first-line therapy, she recommended a 6-month PFR of !30%-56% and for secondline therapy, a 3-month PFR of !40% as an indicator of promising activity, while a 6-month PFR of 20% would suggest inactivity of a novel compound. In our ASPS METþ group, the 3-and 6-month cumulative PFR were 85% (95% CI 73.9% to 96.1%) and 55.0% (39.6% to 70.4%), respectively. In an exploratory analysis of our study, in pretreated versus non-pretreated METþ patients, the first-line subset had a 3-and 6-month PFR of 52.6% (95% CI 30.2% to 75.1%) and 42.1% (95% CI 19.9% to 64.3%), respectively. The second-line subset had a 3-and 6-month PFR of 57.1% (95% CI 20.5% to 93.8%) and 14.3% (0.0% to 40.2%), respectively. This post hoc analysis suggests that crizotinib is active in this setting following Van Glabbeke's criteria. It has to be noted, however, that these criteria were developed based on trials involving multiple sarcoma subtypes. The PFS seen with crizotinib in METþ ASPS is better than results achieved in non-selected patients with advanced STS treated with single-agent doxorubicin in first line (4.6 months, 95% CI 2.9-5.6) [18] , or with the oral angiogenesis inhibitor pazopanib in previously treated STS patients (4.6 months, 95% CI 3.7-4.8) [19] . However, the biological behaviour of ASPS is so different from the majority of sarcomas, that the value of comparing the results of this study with all-comer STS studies is relatively limited. In a retrospective database review evaluating the efficacy of pazopanib and/or trabectedin in advanced ASPS patients, the median PFS for pazopanib (N ¼ 29) was 13.6 months (range: 1.6-32.2þ) at 19-month median follow-up and the median PFS for trabectedin (N ¼ 23) was 3.7 months (range: 0.7-109) at 27-months [20] . In our trial, in ASPS with TFE3 gene rearrangement (with about half of the patients previously treated), crizotinib (N ¼ 40) was associated a median PFS of 8.0 months (95% CI 4.1-12.8) and the median OS was not reached after a median 833 days (range: 85-1279).
The tissue blocks collected from our 53 ASPS patients are now the basis for multiple ongoing exploratory studies, to improve our understanding of the biology and the identification of new prognostic/predictive biomarkers and treatment strategies for this rare cancer.
Our study showed variable responses, which suggests the presence of other factors in combination with TFE3 rearrangement which might predict efficacy of crizotinib. As the level of MET expression and/or activation may vary in different ASPS tumours, even with ASPSCR1-TFE3 fusion present, it should be thoroughly evaluated using immunohistochemistry for both total and activated forms of the signalling pathway components. Furthermore, the level of MET gene expression could be assessed utilising in situ hybridisation or quantitative polymerase chain reaction. This translational part of the project is on-going, using leftover material. In addition, we are currently performing correlative studies using whole exome sequencing to evaluate the mutational profile and perform low-coverage whole genome sequencing to study copy number changes, which will be supplemented by research using tissue microarrays constructed from the tissue blocks, to better understand the molecular background of ASPS and the sensitivity or resistance of individual cases to crizotinib.
The range of adverse events observed in this study was consistent with safety data for crizotinib in NSCLC patients. No new types of adverse events were observed in ASPS. Dose intensity was high and the incidence of dose modifications due to toxicity was moderate.
This study illustrates some of the methodological limitations using response rate in early clinical trials in oncology. Our study's primary end point was chosen based on the volumetric responses seen with crizotinib in the labelled indication of ALKþ NSCLC and due to the absence of reliable reference data on PFS or PFR in ASPS. In general, EORTC is recommending the use of timerelated end points such as PFR during the early exploration of novel agents in STS [17] , which provided the phase II rationale for at least two successful registration trials in STS in the past years [19, 21] .
We currently see more trial activity in ASPS than in the past. Most trials focus on angiogenesis inhibitors, which can induce a clinically relevant reduction in tumour burden in individual patients. NCT01337401 (CASPS), evaluating the efficacy and safety of cediranib versus placebo (with crossover to cediranib), used a somewhat artificial primary end point measuring the percentage change in the sum of target marker lesion diameters from baseline to week 24 (or progression if sooner). The study met its primary end point. PR was observed with cediranib in 6/28 ASPS patients versus 0/16 patients on placebo, SD occurred in 19/28 (68%) of patients on cediranib and 12/16 (75%) on placebo. The median PFS was 10.8 months for cediranib versus 3.7 months for placebo (hazard ratio: 0.54; 90% CI 0.30-0.97, P ¼ 0.041) [22] . Cediranib is also being tested in two other studies (NCT00942877 and NCT01391962). Other antiangiogenic agents under evaluation in ASPS are pazopanib (NCT02113826) and sunitinib (NCT01391962).
In this study in patients with advanced or metastatic ASPS with central determination of rearrangement of TFE3, we were able to demonstrate that crizotinib is an active compound for ASPS, given the DCR and PFR observed in this histotype-specific trial. We would recommend for future early clinical trials involving novel targeted therapies for ASPS that end points such as DCR, PFS and/or PFR should be considered.
